BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Idiopathic Inflammatory Myopathies readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Idiopathic Inflammato
 ry Myopathies\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06455449-5367@assetmemo.bio
DTSTAMP:20261122T012611Z
DTSTART;VALUE=DATE:20280110
DTEND;VALUE=DATE:20280111
SUMMARY:Anifrolumab: Phase 3 readout est. (NCT06455449)
DESCRIPTION:Anifrolumab\, phase 3\, Idiopathic Inflammatory Myopathies.\nSt
 udy: A Study to Investigate the Efficacy and Safety of Anifrolumab Adminis
 tered as Subcutaneous Injection and Added to Standard of Care Compared Wit
 h Placebo Added to Standard of Care in Adult Participants With Idiopathic 
 Inflammatory Myopathies (Polymyositis and Dermatomyositis)\nEstimated prim
 ary completion: 10 January 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/anifrolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06455449
URL:https://assetmemo.bio/drug/anifrolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
